Doxorubicin-conjugated magnetic nanoparticles containing hydrolyzable hydrazone bonds were developed using a non-toxic poly[N-(2-hydroxypropyl)methacrylamide] (PHPMA) coating, which ensured good colloidal stability in aqueous media and limited internalization by the cells, however, enabled adhesion to the cell surface. While the neat PHPMA-coated particles proved to be non-toxic, doxorubicin-conjugated particles exhibited enhanced cytotoxicity in both drug-sensitive and drug-resistant tumor cells compared to free doxorubicin. The newly developed doxorubicin-conjugated PHPMA-coated magnetic particles seem to be a promising magnetically targeted vehicle for anticancer drug delivery.

Danylo Halytsky Lviv National Medical University Pekarska Str 69 Lviv 79000 Ukraine

Department of Regulation of Cell Proliferation and Apoptosis Institute of Cell Biology NAS of Ukraine Drahomanov Str 14 16 Lviv 79005 Ukraine

Inorganic Chemistry and Center for Nanointegration University of Duisburg Essen Universitaetsstr 5 7 D 45117 Essen Germany

Institute of Experimental Medicine CAS Vídeňská 1083 142 20 Prague 4 Czech Republic

Institute of Macromolecular Chemistry CAS Heyrovského nám 2 162 06 Prague 6 Czech Republic

Zobrazit více v PubMed

Carvalho C, Santos R X, Cardoso S, Correia S, Oliveira P J, Santos M S, Moreira P I. Curr Med Chem. 2009;16:3267–3285. doi: 10.2174/092986709788803312. PubMed DOI

Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Pharmacol Rev. 2004;56:185–229. doi: 10.1124/pr.56.2.6. PubMed DOI

Denny W A. Anti-Cancer Drug Des. 1988;4:241–249. PubMed

Octavia Y, Tocchetti C G, Gabrielson K L, Janssens S, Crijns H J, Moens A L. J Mol Cell Cardiol. 2012;52:1213–1225. doi: 10.1016/j.yjmcc.2012.03.006. PubMed DOI

Akbarzadeh A, Mikaeili H, Zarghami N, Mohammad R, Barkhordari A, Davaran S. Int J Nanomed. 2012;7:511–526. doi: 10.2147/IJN.S24326. PubMed DOI PMC

Annovazzi L, Caldera V, Mellai M, Riganti C, Battaglia L, Chirio D, Melcarne A, Schiffer D. Int J Oncol. 2015;46:2299–2308. doi: 10.3892/ijo.2015.2963. PubMed DOI PMC

Chertok B, Moffat B A, David A E, Yu F, Bergemann C, Ross B D, Yang V C. Biomaterials. 2008;29:487–496. doi: 10.1016/j.biomaterials.2007.08.050. PubMed DOI PMC

Ladj R, Bitar A, Eissa M, Mugnier Y, Le Dantec R, Fessi H, Elaissari A. J Mater Chem B. 2013;1:1381–1396. doi: 10.1039/c2tb00301e. PubMed DOI

Lima-Tenório M K, Gómez Pineda E A, Ahmad N M, Fessi H, Elaissari A. Int J Pharm. 2015;493:313–327. doi: 10.1016/j.ijpharm.2015.07.059. PubMed DOI

Horák D, Babič M, Macková H, Beneš M J. J Sep Sci. 2007;30:1751–1772. doi: 10.1002/jssc.200700088. PubMed DOI

Ladj R, Bitar A, Eissa M M, Fessi H, Mugnier Y, Le Dantec R, Elaissari A. Int J Pharm. 2013;458:230–241. doi: 10.1016/j.ijpharm.2013.09.001. PubMed DOI

Lima-Tenório M K, Gómez Pineda E A, Ahmad N M, Agusti G, Manzoor S, Kabbaj D, Fessi H, Elaissari A. Colloids Surf, B. 2016;145:373–381. doi: 10.1016/j.colsurfb.2016.05.020. PubMed DOI

Garay R P, El-Gewely R, Armstrong J K, Garratty G, Richette P. Expert Opin Drug Delivery. 2012;9:1319–1323. doi: 10.1517/17425247.2012.720969. PubMed DOI

Paluska E, Hrubá A, Štĕrba O, Kopeček J. Folia Biol (Prague, Czech Repub) 1986;32:91–102. PubMed

Fanciullino R, Ciccolini J, Milano G. Crit Rev Oncol Hematol. 2013;88:504–513. doi: 10.1016/j.critrevonc.2013.06.010. PubMed DOI

Ulbrich K, Šubr V, Strohalm J, Plocová D, Jelínková M, Říhová B. J Controlled Release. 2000;64:63–79. doi: 10.1016/S0168-3659(99)00141-8. PubMed DOI

Babič M, Horák D, Trchová M, Jendelová P, Glogarová K, Lesný P, Herynek V, Hájek M, Syková E. Bioconjugate Chem. 2008;19:740–750. doi: 10.1021/bc700410z. PubMed DOI

Ulbrich K, Holá K, Šubr V, Bakandritsos A, Tuček J, Zbořil R. Chem Rev. 2016;116:5338–5431. doi: 10.1021/acs.chemrev.5b00589. PubMed DOI

Kopeček J, Kopečková P. Adv Drug Delivery Rev. 2010;62:122–149. doi: 10.1016/j.addr.2009.10.004. PubMed DOI PMC

Peterson C M, Shiah J-G, Sun Y, Kopečková P, Minko T, Straight R C, Kopeček J. HPMA copolymer delivery of chemotherapy and photodynamic therapy of ovarian cancer. In: Maeda H, Kabanov A, Kataoka K, et al., editors. Polymer Drugs in the Clinical Stage. New York, NY, USA: Kluwer Academic; 2003. pp. 101–123. PubMed

Luo K, Yang J, Kopečková P, Kopeček J. Macromolecules. 2011;44:2481–2488. doi: 10.1021/ma102574e. PubMed DOI PMC

Serna C J, Morales M P. Maghemite (γ-Fe2O3): A versatile magnetic colloidal material. In: Matijević E, Borkovec M, editors. Surface and Colloids Science. Vol. 17. New York, NY, USA: Kluwer Academic; 2004. pp. 27–81. DOI

Moskvin M, Babič M, Reis S, Cruz M M, Ferreira L P, Deus Carvalho M, Costa Lima S A, Horák D. Colloids Surf, B. 2018;161:35–41. doi: 10.1016/j.colsurfb.2017.10.034. PubMed DOI

Gottesman M M, Fojo T, Bates S E. Nat Rev Cancer. 2002;2:48–58. doi: 10.1038/nrc706. PubMed DOI

Faraji A H, Wipf P. Bioorg Med Chem. 2009;17:2950–2962. doi: 10.1016/j.bmc.2009.02.043. PubMed DOI

Mody V V, Cox A, Shah S, Singh A, Bevins W, Parihar H. Appl Nanosci. 2014;4:385–392. doi: 10.1007/s13204-013-0216-y. DOI

Hydrophilic Copolymers with Hydroxamic Acid Groups as a Protective Biocompatible Coating of Maghemite Nanoparticles: Synthesis, Physico-Chemical Characterization and MRI Biodistribution Study

Metal Oxide Nanoparticles: Review of Synthesis, Characterization and Biological Effects